Evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetes

BACKGROUND: Patients with any form of diabetes during pregnancy should achieve the target (close to physiological) values of glycaemia, the main condition for a safe course and outcomes of pregnancy. To accomplish this task, effective and safe methods of insulin therapy should be selected. AIM: To d...

Full description

Bibliographic Details
Main Authors: Alena V. Tiselko, Maria I. Yarmolinskaya, Elena V. Misharina, Yuliya P. Milyutina
Format: Article
Language:English
Published: Endocrinology Research Centre 2019-12-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/10214
_version_ 1797255157693546496
author Alena V. Tiselko
Maria I. Yarmolinskaya
Elena V. Misharina
Yuliya P. Milyutina
author_facet Alena V. Tiselko
Maria I. Yarmolinskaya
Elena V. Misharina
Yuliya P. Milyutina
author_sort Alena V. Tiselko
collection DOAJ
description BACKGROUND: Patients with any form of diabetes during pregnancy should achieve the target (close to physiological) values of glycaemia, the main condition for a safe course and outcomes of pregnancy. To accomplish this task, effective and safe methods of insulin therapy should be selected. AIM: To determine the glycaemic profile and pregnancy outcomes in women with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) and multiple insulin injections (MII). METHODS: A continuous glucose monitoring (CGM) of 100 pregnant women with type 1 diabetes treated with CSII and 100 women treated with MII was conducted to assess the effectiveness of these insulin therapy regimens in achieving target blood glucose values. RESULTS: HbA1c levels were significantly lower during the first, second, and third trimesters in patients treated with CSII than those treated with MII. Glucose variability has already improved since the second trimester of pregnancy in women treated with CSII, which was not observed in those treated with MII. The period of hyperglycaemia according to the results in pregnant women treated with CSII was 25 [13; 38] %, which was lower than those treated with MII, 41 [18; 54] %. No risk of obstetric and perinatal complications was observed with the duration of the hyperglycaemic state of <25% of the CGM time, whereas the risk of neonatal hypoglycaemia appeared with the duration of the hypoglycaemic state of a mother with type 1 diabetes of >0.2%. The relationship between glucose variability in terms of MAGE and MODD and the risk of developing macrosomia has been observed, and the dependence of glucose variability (MODD and CONGA) and the risk of neonatal hypoglycaemia and preeclampsia have also been confirmed. CONCLUSION: Comprehensive assessment of the glycaemic profile when using CSII, confirmed the advantages of using CSII in pregnant women with type 1 diabetes to achieve the target glycaemia values, to reduce glucose variability and duration of hypoglycaemic episodes, which led to decreased frequency of obstetric and perinatal complications.
first_indexed 2024-03-08T15:20:20Z
format Article
id doaj.art-842146e7f4e74abe801c1178d679c3e6
institution Directory Open Access Journal
issn 2072-0351
2072-0378
language English
last_indexed 2024-04-24T22:01:23Z
publishDate 2019-12-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj.art-842146e7f4e74abe801c1178d679c3e62024-03-20T11:48:02ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782019-12-0122652653510.14341/DM1021410446Evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetesAlena V. Tiselko0Maria I. Yarmolinskaya1Elena V. Misharina2Yuliya P. Milyutina3The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O.OttThe Research Institute of Obstetrics, Gynecology and Reproductology named after D.O.OttThe Research Institute of Obstetrics, Gynecology and Reproductology named after D.O.OttThe Research Institute of Obstetrics, Gynecology and Reproductology named after D.O.OttBACKGROUND: Patients with any form of diabetes during pregnancy should achieve the target (close to physiological) values of glycaemia, the main condition for a safe course and outcomes of pregnancy. To accomplish this task, effective and safe methods of insulin therapy should be selected. AIM: To determine the glycaemic profile and pregnancy outcomes in women with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) and multiple insulin injections (MII). METHODS: A continuous glucose monitoring (CGM) of 100 pregnant women with type 1 diabetes treated with CSII and 100 women treated with MII was conducted to assess the effectiveness of these insulin therapy regimens in achieving target blood glucose values. RESULTS: HbA1c levels were significantly lower during the first, second, and third trimesters in patients treated with CSII than those treated with MII. Glucose variability has already improved since the second trimester of pregnancy in women treated with CSII, which was not observed in those treated with MII. The period of hyperglycaemia according to the results in pregnant women treated with CSII was 25 [13; 38] %, which was lower than those treated with MII, 41 [18; 54] %. No risk of obstetric and perinatal complications was observed with the duration of the hyperglycaemic state of <25% of the CGM time, whereas the risk of neonatal hypoglycaemia appeared with the duration of the hypoglycaemic state of a mother with type 1 diabetes of >0.2%. The relationship between glucose variability in terms of MAGE and MODD and the risk of developing macrosomia has been observed, and the dependence of glucose variability (MODD and CONGA) and the risk of neonatal hypoglycaemia and preeclampsia have also been confirmed. CONCLUSION: Comprehensive assessment of the glycaemic profile when using CSII, confirmed the advantages of using CSII in pregnant women with type 1 diabetes to achieve the target glycaemia values, to reduce glucose variability and duration of hypoglycaemic episodes, which led to decreased frequency of obstetric and perinatal complications.https://www.dia-endojournals.ru/jour/article/view/10214type 1 diabetes mellituspregnancycontinuous subcutaneous insulin infusioncontinuous glucose monitoringglucose variability
spellingShingle Alena V. Tiselko
Maria I. Yarmolinskaya
Elena V. Misharina
Yuliya P. Milyutina
Evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetes
Сахарный диабет
type 1 diabetes mellitus
pregnancy
continuous subcutaneous insulin infusion
continuous glucose monitoring
glucose variability
title Evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetes
title_full Evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetes
title_fullStr Evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetes
title_full_unstemmed Evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetes
title_short Evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetes
title_sort evaluation of glycaemic profile variability as a basis for insulin therapy strategy in pregnant women with type 1 diabetes
topic type 1 diabetes mellitus
pregnancy
continuous subcutaneous insulin infusion
continuous glucose monitoring
glucose variability
url https://www.dia-endojournals.ru/jour/article/view/10214
work_keys_str_mv AT alenavtiselko evaluationofglycaemicprofilevariabilityasabasisforinsulintherapystrategyinpregnantwomenwithtype1diabetes
AT mariaiyarmolinskaya evaluationofglycaemicprofilevariabilityasabasisforinsulintherapystrategyinpregnantwomenwithtype1diabetes
AT elenavmisharina evaluationofglycaemicprofilevariabilityasabasisforinsulintherapystrategyinpregnantwomenwithtype1diabetes
AT yuliyapmilyutina evaluationofglycaemicprofilevariabilityasabasisforinsulintherapystrategyinpregnantwomenwithtype1diabetes